Gennex Laboratories is planning to raise funds by issuance of equity shares or any other securities, through permissible modes including but not limited to a rights issue, as may be permitted under applicable law and subject to such regulatory/ statutory approvals, as may be required. A meeting of Board of Directors of the Company will be held on April 06, 2022 to consider the same.
Gennex Laboratories is engaged in the manufacture and export of bulk drugs and intermediates. The product range of the company includes Guaiphenesin,Methocarbamol,Fluconazole and Phenazopyridine.
